Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Total Liabilities (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Total Liabilities for 8 consecutive years, with $62.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 22.29% to $62.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.2 million through Dec 2025, down 22.29% year-over-year, with the annual reading at $62.2 million for FY2025, 22.29% down from the prior year.
  • Total Liabilities for Q4 2025 was $62.2 million at Precision Biosciences, down from $76.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $203.5 million in Q1 2021, with the low at $62.2 million in Q4 2025.
  • Average Total Liabilities over 5 years is $126.7 million, with a median of $127.7 million recorded in 2021.
  • The sharpest move saw Total Liabilities surged 105.2% in 2021, then crashed 49.11% in 2025.
  • Over 5 years, Total Liabilities stood at $120.3 million in 2021, then soared by 47.71% to $177.7 million in 2022, then fell by 20.71% to $140.9 million in 2023, then crashed by 43.23% to $80.0 million in 2024, then decreased by 22.29% to $62.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $62.2 million, $76.9 million, and $74.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.